Imaging Studies
Abiant conducts PET neuroimaging studies to measure
pharmacokinetic and pharmacodynamic properties including:
measures using small subject numbers (8 - 20) even when receptor
specific tracers are not available. In all clinical phases, we focus on
high quality data analysis using techniques that overcome noise and
yield quantitative, interpretable, and clinically relevant data.
Abiant conducts PET neuroimaging studies to measure
pharmacokinetic and pharmacodynamic properties including:
- biodistribution / CNS penetration
- receptor occupancy
- functional CNS effects
- potential side effects
- dose response
- endpoint / pathology impact
- comparison to known compounds
measures using small subject numbers (8 - 20) even when receptor
specific tracers are not available. In all clinical phases, we focus on
high quality data analysis using techniques that overcome noise and
yield quantitative, interpretable, and clinically relevant data.
Advanced BioImaging to Accelerate New Therapeutics
| Copyright 2006-2009 Abiant, Inc. |
 | | | | | | | | |
Experience
We have conducted imaging studies a comprehensive array of CNS and non-CNS compounds including
those in the table below. In particular: We have demonstrated a unique ability to obtain central effect
and dose response data on novel compounds for which a receptor specific ligand is not available
and/or representative of downstream effects
those in the table below. In particular: We have demonstrated a unique ability to obtain central effect
and dose response data on novel compounds for which a receptor specific ligand is not available
and/or representative of downstream effects
|
 |
 |
 |
 |
 |
 |
 |
Dr. Mony de Leon is Professor of Psychiatry at the New York University (NYU) School of Medicine and Scientist
at the New York State, Nathan Kline Institute. He received his Gerontology doctorate from Columbia University
in 1980. His published doctoral dissertation described, for the first time, the cortical atrophy of Alzheimer’s
disease in living patients. For over 25 years he has continued to develop imaging and biomarker approaches
for the early diagnosis of Alzheimer’s disease (AD). Among his qualifications, he has published over 200
papers in AD research and founded both the NYU Neuroimaging laboratory and the NYU School of Medicine,
Center for Brain Health (CBH). The CBH is an interdisciplinary clinical research center, funded by the NIH, with
a team of 25 clinicians and scientists. Dr. de Leon is a reviewer and/or editorial board member for 22 journals
and has served on both national and international NIH advisory panels in the area of the early diagnosis of AD.
In 2006, he was voted “Worlds pioneer in the brain imaging of Alzheimer’s disease” at the Alzheimer centennial
in Tubingen, Germany.
at the New York State, Nathan Kline Institute. He received his Gerontology doctorate from Columbia University
in 1980. His published doctoral dissertation described, for the first time, the cortical atrophy of Alzheimer’s
disease in living patients. For over 25 years he has continued to develop imaging and biomarker approaches
for the early diagnosis of Alzheimer’s disease (AD). Among his qualifications, he has published over 200
papers in AD research and founded both the NYU Neuroimaging laboratory and the NYU School of Medicine,
Center for Brain Health (CBH). The CBH is an interdisciplinary clinical research center, funded by the NIH, with
a team of 25 clinicians and scientists. Dr. de Leon is a reviewer and/or editorial board member for 22 journals
and has served on both national and international NIH advisory panels in the area of the early diagnosis of AD.
In 2006, he was voted “Worlds pioneer in the brain imaging of Alzheimer’s disease” at the Alzheimer centennial
in Tubingen, Germany.